YUAN Jie1, XIONG Xi2, LI Yun-jing2, TAN Hua-bing2, LIU Zhi-xin1,3, WANG Ya4, QIU Xue-mei4, LI Bei1, YANG Jing1,2
1.School of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China; 2. Department of Infectious Disease, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China; 3. Department of Respiratory, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China; 4. Pathogen biology laboratory, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China
Abstract:There is a great number of HBV carriers in China. Those people infected with HBV are more likely to develop hepatocellular carcinoma than normal population. We found that the number of CD133 positive liver cancer stem cells in the liver tissue section of HBV carriers was higher than that of the control group. Further studies showed that preS1 could upregulate the related factors of hepatocyte carcinogenesis. Using the technique of immunoprecipitation, we found the interaction between preS1 and β-catenin. preS1 activates Wnt signaling pathway by inhibiting β-catenin phosphorylation, leading to liver cell carcinoma. The results of this study will deepen our understanding of the cancerization of liver cells, and provide a theoretical basis for the prevention and treatment of liver cancer caused by HBV infection in the future.
[1] Liang TJ. Hepatitis B: the virus and disease [J]. Hepatology,2009, 49(5):S13-21. DOI: 10.1002/hep.22881 [2] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 [J]. Lancet, 2015, 386 (10003): 1546-1555. DOI: 10.1016/S0140-6736(15)61412-X [3] Liu C, Chang L, Ji HM, et al. Prevalence of HBV DNA among 20 million seronegative blood donations in China from 2010 to 2015 [J]. Sci Rep, 2016, 6(1):36464. DOI: 10.1038/ srep 36464 [4] Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma [J]. N Engl J Med, 2002, 347(21):168-174. DOI: 10.1056/NEJM200211213472119 [5] Zhao LH, Liu X, Yan HX, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma [J]. Nat Commnu, 2016, 7(1): 12992. DOI: 10.1038/ncomms12992 [6] Thomas T, Magdalena A, Budzinska A, et al. Urban HBV DNA integration: molecular mechanisms and clinical implications [J]. Viruses,2017, 9(4): 75. DOI: 10.3390/v9040075 [7] Chauhan R, Churchill ND, Mulrooney-Cousins PM, et al. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma [J]. Oncogenesis, 2017, 6(4): e317. DOI: 10.1038/ oncsis.2017.22 [8] Clevers H. At the crossroads of inflammation and cancer [J]. Cell, 2004, 118(6):671-674. DOI: 10.1016/j.cell.2004.09.005 [9] Jin YM, Yun C, Park C, et al. Expression of hepatitis B virus X protein is closely correlated with the high periportal inflammatory activity of liver diseases [J]. J Viral Hepat, 2001, 8(5):322-330. DOI: 10.1046/j.1365-2893.2001.00308.x [10] Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma [J]. Nat Rev Cancer, 2013, 13(2):123-135. DOI: 10.1038/nrc3449 [11] Kekule AS, Lauer U, Meyer M, et al. The preS2/S region of integrated hepatitis B virus DNA encodes a transcrip-tional transactivator [J]. Nature, 1990, 343(6257):457-461. DOI: 10.1038/ 343457a0 [12] Fu S, Zhou RR, Li N, et al. Hepatitis B virus X protein in liver tumor microenvironment [J]. Tumour Biol, 2016, 37(12): 15371-15381. DOI: 10.1007/s13277-016-5406-2 [13] Murakami Y, Saigo K, Takashima H, et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas [J]. Gut,2005, 54(8): 1162-1168. DOI: 10.1136/gut.2004.054452 [14] Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma [J]. J Hepatol, 2005, 42(5):760-777. DOI: 10.1016/j.jhep.2005.02.005 [15] Murakami Y, Minami M, Daimon Y, et al. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen [J]. J Med Virol, 2004, 72(2): 203-214. DOI: 10.1002/jmv.10547 [16] Shi Y, Lan Y, Cao F, et al. Infected hematopoietic stem cells and with integrated HBV DNA generate defective T cells in chronic HBV infection patients [J]. J Viral Hepat, 2014, 21(7): e39-e47. DOI: 10.1111/jvh.12236 [17] Liu ZX, Dai XC, Wang TC, et al. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells [J]. Cancer Lett, 2017, 400(1):149-160. DOI: 10.1016/j.canlet.2017.04.017 [18] Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway [J]. Oncogene,2008, 27(12): 1749-1758. DOI: 10.1038/sj.onc.1210811 [19] Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma [J]. Hepatology, 2009, 49(1): 318-329. DOI: 10.1002/hep.22704 [20] Clevers H, Nusse R. Wnt/β-catenin signaling and disease[J]. Cell,2012, 149(6): 1192-11205. DOI: 10.1016/j.cell.2012.05.012 [21] Katoh M. WNT signaling pathway and stem cell signaling network[J]. Clin Cancer Res, 2007, 13(14): 4042-4045. DOI: 10.1158/1078-0432.CCR-06-2316 [22] Hoffmeyer K, Raggioli A, Rudloff S, et al. Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells[J]. Science,2012, 336(6088):1549-1554. DOI: 10.1126/science. 1218370